CMTx R2
Infectious diseases (host-directed treatment)
Pre-clinicalActive
Key Facts
Indication
Infectious diseases (host-directed treatment)
Phase
Pre-clinical
Status
Active
Company
About CMTx Biotech
CMTx Biotech is a U.S.-based biotech firm leveraging a drug repurposing and rescue platform to develop host-directed therapeutics for CBRN threats and severe infections. Its lead asset, incyclinide, has completed IND-enabling studies, and a second candidate, CMTx R2, is an internationally approved drug being repositioned. The company is led by a seasoned management team with expertise in drug development and commercialization, and it maintains collaborations with key academic institutions to advance its pipeline. CMTx operates as a pre-revenue, private entity targeting government and public health markets for medical countermeasures.
View full company profile